A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Abroad (travel likely)Recruiting

Conditions

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Universitaetsklinik Heidelberg, Heidelberg, Germany

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy

Abroad (travel likely)RecruitingPHASE4

Sankt Pölten, Austria · Vienna, Austria

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis

Abroad (travel likely)RecruitingPHASE3

La Jolla, United States · Los Angeles, United States

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

ATTR-CM

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

Quantitative-imaging in Cardiac Transthyretin Amyloidosis

ATTR-CM

Abroad (travel likely)Recruiting

Groningen, Netherlands